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ABSTRACT
Brain and spinal cord tuberculosis  are one of the commonest neurological infection in developing countries. Its 
associated with high morbidity and mortality. Diagnosis is based on clinical features, cerebrospinal fluid and brain 
imaging. Combination of antituberculous drugs should be started as early as possible to prevent the complications. The 
patient's clinical stage at presentation is the most important prognostic factor. Surgical procedures are directed at 
management of the hydrocephalus. Focal lesions, intracranial tuberculomas, and tuberculous abscesses, are usually 
located in cerebral or cerebellar hemispheres, uncommonly in brainstem and very rarely in spinal cord. They do not 
usually require surgical intervention and respond well to antituberculous treatment, along with corticosteroids. All these 
fsctors pertaining to tuberculosis of brain and spine will be adressed in this review article.
R E V I E W  A R T I C L E
INTORODUCTION:
Tuberculosis remains a major public health problem 
and a concern globaly after its resurgence in developed 
countries.1 Several risk factors have been identified for 
this phenomenon.2 These include the over-crowding, 
malnutrition, multi drug-resistant strains of 
tuberculosis, ineffective tuberculosis control 
programmes and increasing prevalence of HIV 
infection. The incidence of tuberculosis varies from 9 
cases per 100 000 population per year to as high as 
110-165 cases per 100 000 population in the 
developing countries of Asia and Africa.3 Tuberculous 
involvement of the central nervous system (CNS) is an 
important and fatal extra-pulmonary type. 
Approximately 10% of all patients with tuberculosis 
have CNS involvement.4  Its incidence is directly 
proportional to the prevalence of tuberculosis infection 
in general population. In developing countries CNS 
tuberculosis is a disease of younger age group.5 
We have searched Pubmed central with a keyword of 
central nervous system tuberculosis. A total of 2557 
articles were present, however when we restrict it to the 
last five years, than 185 articles left.
Tuberculous meningitis (TBM) is associated with very 
high morbidity. Early treatment is important because 
the outcome correlates closely with the stage of TBM at 
the time the treatment is initiated.6 TBM accounts for 
2-45 of all types of tuberculosis (TB) among children 
when compared with only 2.9-5.8% of adult TB.7 Most 
studies have suggested that combination of various 
factors like delayed diagnosis and treatment and 
advanced stages disease at presentation many 
contribute to the high morbidity and mortality rate.8 
Tuberculosis (TB) kills 2 million people each year in the 
world with significant proportion of TBM, of which 
250,000 are children.9 Accurate and early recognition 
of the disease and effective treatment of TBM is 
important.10 Although children and adults are at equal 
risk to develop TB when exposed to a person with an 
infectious TB, but children are substantially at greater 
risk of developing TB especially miliary TB and TBM.11
Factors that determine the risk of TB are difficult to 
interpret. Prolonged and close exposure to infectious 
cases, malnutrition, lack of vaccination, poverty, and 
lack of early recognition at either pulmonary 
tuberculosis or TBM stage I and II are the major risk 
factors.12 TBM is well recognized entity but there are 
few more types of central nervous system tuberculosis 
like tuberculoma, tuberculous brain abscess and 
tuberculous encephalopathy. Being part of an area 
where TB is endemic, we have huge number of these 
clinical entities as well but they are poorly recognized 
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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and may need to be considered when other causes are 
excluded. Mortality in TBM was significantly related to 
pre-admission illness, duration and CSF findings and 
brain imaging findings. Mortality can be reduced by 
early and appropriate recognition. Antituberculous 
drugs and supportive therapy should be initiated 
promptly followed by supportive measures to prevent 
the long term complications.13 Children who develop 
pulmonary tuberculosis are least likely to have cavity 
lesions, thus very unlikely to be sputum smear positive 
an it hinders the diagnosis. The detection of 
mycobacterium tuberculosis genome in the 
cerebrospinal fluid via the polymeraze chain reaction 
(PCR) test serves a useful test for early diagnosis but it 
is costly. Although the availability is limited and it is 
expensive, but when the diagnosis is doubtful they may 
help in diagnosis.10 
Diagnosis of TBM is based on clinical evaluation since 
the bacteriological diagnosis takes time and has a low 
yield.11 However cerebrospinal fluid (CSF) and brain 
imaging are extremely powerful investigative tools for 
diagnosis, management and follow up assessment of 
these patients. CNS tuberculosis is endemic in many 
parts of world and recently its prevalence has been on 
the rise worldwide as a result of increased number of 
AIDS cases.1 Since early diagnosis will result in earlier 
recognition and treatment, radiologic images may play 
a critical role in patient management. CT and MR 
imaging are the main imaging techniques used in its 
localization and characterization.13 The imaging 
features overlap with other intracranial diseases, such 
as cysticercosis, metastases, and primary brain 
neoplasm. Recently, in vivo proton MR spectroscopy 
has been found to be helpful in better characterizing 
such lesions; however, it may not always be possible to 
evaluate lesions smaller than 10 mm with in vivo 
spectroscopy owing to its sensitivity constraints. 
 
Classification of CNS tuberculosis
Intracranial 
• TBM  
• TBM with miliary tuberculosis 
• Tuberculous encephalopathy 
• Tuberculous vasculopathy 
• Ttuberculoma / Tuberculous abscess 
Spinal 
• Pott's spine and Pott's paraplegia 
• Tuberculousarachnoiditis (myeloradiculopathy) 
• Non-osseous spinal tuberculoma 
• Spinal meningitis
Pathophysiology:
Most tuberculous infections of the CNS are caused by 
Mycobacterium tuberculosis. Less frequently, other 
mycobacteria may be involved. bacilli reach the CNS by 
the haematogenous route secondary to disease 
elsewhere in the body 6. CNS tuberculosis develops in 
two stages. Initially small tuberculous lesions (Rich's 
foci) develop in the CNS, either during the stage of 
bacteraemia of the primary tuberculous infection or 
shortly afterwards. These initial tuberculous lesions 
may be in the meninges, the subpial or subependymal 
surface of the brain or the spinal cord, and may remain 
dormant for years after initial infection.14
Later, rupture or growth of one or more of these small 
tuberculous lesions produces development of various 
types of CNS tuberculosis.7 Specific stimulus for 
rupture or growth of Rich's foci is not known, although 
immunological mechanisms may play a role. Rupture 
into the subarachnoid space or into the ventricular 
system results in meningitis. The type and extent of 
lesions that result from the discharge of tuberculous 
bacilli into the cerebrospinal fluid (CSF), depend upon 
the number and virulence of the bacilli, and the 
immune response of the host. Infrequently, infection 
spreads to the CNS from a site of tuberculous otitis or 
calvarial osteitis.8
The pathogenesis of localised brain lesions is also 
thought to involve haematogenous spread from a 
primary focus in the lung (which is visible on the chest 
radiograph in only 30% of cases). It has been 
suggested that with a sizeable inoculation or in the 
absence of an adequate cell-mediated immunity, the 
parenchymal cerebral tuberculous foci may develop 
into tuberculoma or tuberculous brain abscess.9 
In TBM a thick, gelatinous exudate around the 
brainstem leading to hydrocephalus as a consequence 
of obstruction of the basal cisterns, outflow of the 
fourth ventricle, or occlusion of the cerebral aqueduct. 
Hydrocephalus frequently develops in children and is 
associated with a poor prognosis. Basal exudates of 
tuberculosis are usually more severe in the vicinity of 
the circle of Willis, and produce a vasculitis-like 
syndrome and inflammatory changes.12 
CLINICAL FEATURES:
In most patients with TBM there is a history of vague ill 
health lasting 2-8 weeks prior to the development of 
meningeal irritation. These non-specific symptoms 
include malaise, anorexia, fatigue, fever, myalgias, and 
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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headache. The prodromal symptoms in infants include 
irritability, drowsiness, poor feeding, and abdominal 
pain. Eventually, the headache worsens and becomes 
continuous. Bulging fontanelles develop in infants, who 
become increasingly irritable. Nausea, vomiting and 
altered sensorium may develop. Continuous low-grade 
pyrexia is typically present in about 80% of patients. A 
prior history of tuberculosis is present in approximately 
50% of children with TBM and 10% of adult patients.1,3 
Cranial nerve palsies occur in 20-30% of patients and 
may be the presenting manifestation of TBM. The sixth 
cranial nerve is most commonly affected. Vision loss 
due to optic nerve involvement may occasionally be a 
dominant and presenting illness. Ophthalmoscopic 
examination may reveal papilloedema. Funduscopy 
may reveal choroid tubercles, yellow lesions with 
indistinct borders present either singly or in clusters. 
These choroid tubercles are more frequent with TBM 
associated with miliary tuberculosis and are virtually 
pathognomonic of tuberculous aetiology, although they 
are present in only 10% of patients in whom the 
meningitis is not associated with miliary 
involvement.7,12 
Hemiplegia may occur at the onset of the disease or at 
a later stage. Quadriplegia secondary to bilateral 
infarction or severe cerebral oedema is less common 
and occurs only at an advanced stage in a few patients. 
At times, abnormal movements may dominate the 
clinical picture. Choreiform or hemiballistic movements, 
athetosis, generalised tremors, myoclonic jerks and 
ataxia have been observed, more commonly in children 
than in adults. Seizures, either focal or generalised, 
may occur during acute illness or months after 
treatment.7 Apathy and irritability tend to progress to 
increasing lethargy, confusion, stupor and coma. The 
terminal illness is characterised by deep coma, 
decerebrate or decorticate rigidity, and spasm. 
DIAGNOSIS
Preadmission illness of more than 2 weeks, lack of BCG 
vaccination, history of measles, 3rd degree 
malnutrition, contact to a TB patient among parents 
were seems to be important factors. Neurological 
findings including depressed sensorium, cranial nerve 
palsies, hemiplegia, hydrocephalus, CSF findings, brain 
imaging findings, and tuberculomas are important 
findings. 
Diagnosis of TBM based on clinical history and 
examination findings, cerebrospinal fluid (CSF) findings 
and tomography of brain. CT scan has been proved 
helpful in diagnosis and evaluation of the complications 
of TBM. Modified Kenneth Jones Criteria have 
significant capacity for the early diagnosis of TBM if 
combined with history (prolonged illness) and clinical 
examination (CNS Symptoms like coma, hemiplegia, 
cranial nerve palsy, fits) along with CSF findings and 
brain imaging. 
The abnormalities found in CSF of untreated patients 
with TBM are well described. Usually, there is a 
predominant lymphocytic reaction (60-400 white cells 
per ml) with raised protein levels (0.8-4 g/l). In the early 
stages of infection, a significant number of 
polymorphonuclear cells may be observed, but over the 
course of several days to weeks they are typically 
replaced by lymphocytes. There is a gradual decrease 
in the sugar concentration of the CSF, which is usually 
less than 50% of serum glucose concentration, the 
values may range between 18-45 mg/dl.10,12  Definitive 
diagnosis of TBM depends upon the detection of the 
tubercle bacilli in the CSF, either by smear examination 
or by bacterial culture and highest detection rates being 
achieved in ventricular fluid. Rates of positivity for 
clinically diagnosed cases range from 25% to 70%.11 
Antibodies against tubercle bacilli can be detected with 
enzyme-linked immunosorbent assay (ELISA) with 
variable success,. latex particle agglutination test, 
which allows the rapid detection of tubercle bacillus 
antigen in CSF.16 The intradermal tuberculin skin test 
is helpful when positive. The test may, however, be 
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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Diagnostic features of TBM
Clinical
• fever and headache (for more than 14 days)
• vomiting  
• altered sensorium or focal neurological deficit
CSF
• pleocytosis (more than 20 cells, more than 60% lymphocytes)  
• increased proteins (more than 100 mg/dl)  
• low sugar (less than 60% of corresponding blood sugar)
• India ink studies and microscopy for malignant cells should be negative
Imaging
• exudates in basal cisterns or in sylvian fissure hydrocephalus
• infarcts (basal ganglionic)
• gyral enhancement  
• tuberculoma formation  
Evidence of tuberculosis elsewhere
Methods to increase mycobacterial yield of CSF smear examination
• examine the deposit on centrifugation of a 10 ml CSF sample  
• examine the deposit for at least 30 min  
• examine several CSF samples over a few days  
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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falsely negative even in the absence of 
immunosuppression and in association with a positive 
reaction to common antigens used to determine 
anergy. The tuberculin skin test has been reported to be 
negative initially in 50-70% of cases and often 
becomes positive during therapy. The best method for 
diagnosing mycobacterial infection, however, is the 
polymerase chain reaction, in which cDNA probes are 
used to identify mycobacterial RNA or DNA sequences 
in CSF. This test is highly sensitive and specific in the 
diagnosis of TBM.10,11 
IMAGING
Computed tomography (CT) or magnetic resonance 
imaging (MRI) of the brain may reveal thickening and 
intense enhancement of meninges, especially in basilar 
regions. Ventricular enlargement is present in a 
majority of patients. The degree of hydrocephalus 
correlates with the duration of the disease. Infarcts are 
another characteristic imaging feature (figures 1 and 2) 
of TBM.13 The reported frequency of infarcts 
demonstrated by CT varies from 20.5% to 38%, 
however, in general, the incidence of infarction is 
significantly higher on MRI than on CT. Tuberculomas 
are infrequently seen on brain immaging of patients 
with TBMr. Multiple small intracranial tuberculoma are 
frequent when TBM is part of miliary tuberculosis.15,16 
Tuberculous encephalopathy:
Tuberculous encephalopathy, a syndrome exclusively 
present in infants and children, has been described 
with pulmonary tuberculosis.17 The characteristic 
features of this entity are the development of a diffuse 
cerebral disorder in the form of convulsions, stupor and 
coma without signs of meningeal irritation or focal 
neurological deficit. CSF is largely normal or may show 
a slight increase in proteins and cells. Pathologically, 
there is diffuse oedema of cerebral white matter with 
loss of neurons in grey matter. A picture resembling 
haemorrhagic leukoencephalopathy or a 




Tuberculomas are firm, avascular, spherical 
granulomatous masses, measuring about 2-8 cm in 
diameter.18 They are well limited from surrounding 
brain tissue which is compressed around the lesion and 
shows oedema and gliosis. The inside of these masses 
may contain necrotic areas composed of caseous 
material, occasionally thick and purulent, in which 
tubercle bacilli can be demonstrated. In developing 
countries young adults and children are predominantly 
affected while in developed countries they are more 
common in older patients.19 The symptoms produced 
by tuberculoma are related to their location. Low-grade 
fever, headache vomiting, seizures, focal neurological 
deficit, and papilloedema are characteristic clinical 
features of supratentorial tuberculomas. Intratentorial 
tuberculomas are more common in children and may 
present with brainstem syndromes, cerebellar 
manifestations, and multiple cranial nerve palsies.20 
On CT, tuberculomas are characterised as low- or 
high-density and rounded or lobulated masses and 
show intense homogenous or ring enhancement after 
contrast administration. They have an irregular wall of 
varying thickness. Moderate to marked perilesional 
oedema is frequently present. Tuberculomas may be 
single or multiple and are more common in frontal and 
parietal lobes, usually in parasagittal areas. On CT, the 
`target sign', a central calcification or nidus surrounded 
by a ring that enhances after contrast administration, is 
considered pathognomonic of tuberculoma. On CT 
scanning, tuberculoma measure more than 20 mm in 
diameter, are frequently irregular in outline, and are 
always associated with marked cerebral oedema 
(leading to midline shift) and progressive focal 
neurological deficit. Images after contrast 
administration show ring enhancement. Stereotactic 
diagnostic biopsy can help in establishing an accurate 
diagnosis. 
Tuberculous brain abscess
Tuberculous brain abscess is a condition distinct from 
CNS tuberculoma. In developing countries, tuberculous 
abscesses have been reported in 4% to 7.5% of 
patients with CNS tuberculosis. The histopathological 
diagnosis of tuberculous brain abscess depends on the 
following criteria: microscopic evidence of pus in the 
abscess cavity, microscopic changes in the abscess 
wall, and isolation of M tuberculosis.11,21 Abscesses are 
usually solitary and larger and progress much more 
rapidly than tuberculomas. CT and MRI pictures of a 
tuberculous abscess show a granuloma with a liquid 
centre, however, they are much larger and frequently 
multiloculated and with marked surrounding oedema.
Clinical features include partial seizures, focal 
neurological deficit, and raised intracranial tension. 
Surgical exploration and drainage of pus along with ATT 
produce excellent long-term results.21
 
Tuberculosis of Spinal cord (Pott's spine)
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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It is estimated that involvement of the spine occurs in 
less than 1% of patients with tuberculosis.22 It is a 
leading cause of paraplegia in developing world. 
Infection in the vertebral bodies led to vertebral 
destruction leads to collapse of the body of the vertebra 
along with anterior wedging.23 Spinal cord compression 
in Pott's spine is mainly caused by pressure from a 
paraspinal abscess which is retropharyngeal in the 
cervical region, and spindle shaped in thoracic and 
thoracolumbar regions. Neurological deficits may also 
result from dural invasion by granulation tissue and 
compression from the debris of sequestrated bone, a 
destroyed intervertebral disc, or a dislocated vertebra. 
Neurological involvement can occur at any stage of 
Pott's spine and even years later, when there has been 
apparent healing, because of stretching of the cord in 
the deformed spinal canal. The thoracic spine is 
involved in about majority of cases.24
Typically, there is a history of local pain, tenderness 
over the affected spine or even overlying bony deformity 
in the form of gibbus. Conventional spinal X-rays are 
usually adequate to demonstrate the destruction of 
adjacent vertebral bodies and intervening disc spaces. 
However, MRI spine is the modality of choice. A 
combination of surgical decompression and treatment 
with antituberculous drugs is needed for the majority of 
patients with Pott's paraplegia. A period of 12 months 
of postoperative antituberculous therapy is adequate.25 
Non-osseous spinal cord tuberculosis:
Non-osseous spinal cord tuberculosis can occur in the 
form of tuberculomas. In one of the case series of 
tuberculous paraplegia without evidence of Pott's 
disease and observed that extradural tuberculomas 
occured in 64% while arachnoid lesions without dural 
involvement, and subdural/extramedullary lesions 
occured in 8% of patients in each group. Intramedullary 
tuberculomas are extremely rarely reported, reports 
from developing countries have also been sporadic. The 
clinical features are indistinguishable from those of any 
extramedullary or intramedullary tumour, although 
acute worsening may occur. Intramedullary lesions are 
frequently located in the thoracic region. More than one 
site in the spinal cord may also be affected. One case 
with conus medullaris syndrome has been described. 
Non-osseous spinal cord tuberculomas may increase in 
size while the patient is on antituberculous therapy. MRI 
is the investigation of choice for these lesions.26 
Spinal TB:
A predominantly spinal form of TBM may result from 
rupture of Rich's focus into the spinal arachnoid space 
rather than the basal meninges. The acute form 
presents with fever, headache, and radiating root pains, 
accompanied by myelopathy. The chronic form, usually 
localised to a few segments, presents with progressive 
spinal cord compression and may suggest a spinal cord 
tumour. The characterisic MRI features include CSF 
loculation and obliteration of the spinal subarachnoid 
space with loss of outline of spinal cord in the 
cervico-thoracic region and matting of nerve roots in 
the lumbar region. Spinal forms of TBM may be 
associated with syrinx formation.22,27 
Tuberculous arachnoiditis: 
Tuberculous arachnoiditis is a relatively common cause 
of myeloradiculopathy in countries endemic for 
tuberculosis. The inflammatory exudate surrounds, but 
does not infiltrate, the spinal cord and nerve roots. 
Neuronal structures are damaged by direct 
compression as well as by ischaemia. The changes of 
arachnoiditis may be focal, multifocal, or diffuse.24 In 
tuberculous arachnoiditis features of spinal cord or 
nerve root involvement may predominate but most 
often there is a mixed picture. Frequently, there is 
clinical evidence of multifocal radiculomyelopathy, but 
even when meningeal involvement is widespread, 
symptoms may arise from a single level. The hallmark 
of diagnosis is the characteristic myelographic picture, 
showing poor flow of contrast material with multiple 
irregular filling defects, cyst formation, and sometimes 
spinal block. The CSF changes are those of a chronic 
meningitis. These patients need adequate 
antituberculous treatment for at least one year. If the 
patient does not respond to medical treatment, surgery 
may be required.28
Management
In majority of children, there is sifnificant improvemt 
with oral drugs over 4 to 6 weeks. Recommended 
treatment includes isoniazid (10-20 mg/kg/day up to 
300 mg), rifampicin (10-20 mg/kg/day, up to 600 
mg/day) and pyrazinamide (15-30 mg/kg/day, up to 2 
grams a da).30. Patients should be monitored for 
Causes of parapalegia in CNS tuberculosis
• Pott's paraplegia  
• non-osseous compressive myelopathies (tuberculoma): extradural, intradural, 
extramedullary, intramedullary  
• transverse myelitis  
• spinal meningitis  
• spinal tuberculous abscess
• tuberculous arachnoiditis (myeloradiculopathy)  
• syrinx formation
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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Indications for corticosteroids in TBM
• altered sensorium  
• focal neurological deficit
• spinal fluid pressure in excess of 300 mmH2O
• spinal block (CSF protein > 400 mg/dl)  
• presence of tuberculomas  
• basilar exudates MRC staging of TBM
Stage I: prodromal phase with no definite neurological symptoms  
Stage II: signs of meningeal irritation with slight or no clouding of sensorium and 
minor (cranial nerve palsies), or no neurological deficit  
Stage III: severe clouding of sensorium, convulsions, focal neurological deficit and 
involuntary movements  
Worst prognostic factors for TBM
• Stage III (mortality 50-70%) 
• extreme of ages  
• malnutrition  
• presence of miliary disease  
• presence of underlying debilitating disease, eg, alcoholism  
• hydrocephalus
• focal neurological deficit
• low CSF glucose levels
• markedly elevated CSF protein  
hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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hepatotoxicity from rifampicin which is seen in up to 
20% of patients. Ethambutol or streptomycin may be 
added if the response is not satisfactory. The duration 
of therapy should be at least 9 months and in some 
instances up to 12-15 months treatment is required. 
The World Health Organization (WHO) put CNS 
tuberculosis under TB treatment Category 1, and 
recommend initial phase therapy (for 2 months) with 
streptomycin, isoniazid, rifamipicin and pyrazinamide, 
followed by a 10 month continuation phase with 
isoniazid and rifampicin. A similar drug regimen has 
been recommended for all forms of CNS tuberculosis. 
In case of  drug resistence and side effects, 2nd line 
derug can be considered which includes azithromycin 
(500-100 mg/day) and clarithromycin (500 to 1000 
mg/day) and ciprofloxacin.23 
ROLE OF CORTICOSTEROIDS:
One of the controversial aspects of treatment of TBM is 
the use of corticosteroids. The response to steroids 
may be dramatic with rapid clearing of sensorium, 
regression of abnomalities of CSF, defervescence and 
relief of headache. They observed that, in addition to 
survival, corticosteroids significantly improved 
intellectual outcome and enhanced resolution of the 
basal exudates and intracranial tuberculoma were 
shown by serial CT scanning. Prednisolone treatment 
(1-3 mg/kg/day) is suggested in patients with TBM. The 
dosage may reduced by 50% in the second and third 
week and then be tapered gradually over the next 4 
weeks.23 
PARADOXICAL WORSENING:
It has been observed frequently that intracranial 
tuberculomas appear or paradoxically increase in size 
while patients are being treated for TBM or 
tuberculoma. These lesions are usually discovered 
accidentally when follow-up CT scan is performed 
routinely or when new neurological signs develop during 
the course of antituberculous therapy. A recent study 
noted that about 8% of patients developed 
asymptomatic tuberculoma during the first month of 
treatment. Concomitant steroid therapy probably has a 
preventive role against these focal lesions.18 
SURGERY
Surgical procedures in patients with TBM are primarily 
directed to the treatment of hydrocephalus. Serial 
lumbar punctures with diuretics and osmotic agents are 
useful measure to relieve elevated intracranial 
pressure. If these steps fail, ventriculo-peritoneal shunt 
may relieve the signs and symptoms of hydrocephalus. 
Early shunting with drug therapy may offer the best 
therapeutic outcome. Intracranial tuberculomas that 
act as single space-occupying lesions with midline 
shifts and increased intracranial pressure, and that fail 
to respond to chemotherapy should be surgically 
removed. If these tuberculomas removed early during 
the cource of illness, prognosis is is exellent.29
 
PROGNOSIS AND SEQUELAE:
The single most important determinant of outcome, for 
both survival and sequelae, is the stage of TBM at 
which treatment has been started. If treatment is 
started in stage I, mortality and morbidity is very low, 
while in stage III almost 50% of patients die, and those 
who recover may have some form of neurological 
deficit. About 20% to 30% of survivors manifest a 
variety of neurological sequelae, the most important of 
which are mental retardation, psychiatric disorders, 
seizures, blindness, deafness, ophthalmoplegia and 
hemiparesis. Endocrinopathies may become evident 
months or year after recovery. The endocrinopathies are 
most probably due to progressive damage of either the 
hypothalamus itself or adjacent basal cisterns. Obesity, 
hypogonadism, diabetes inspidus, and growth 
retardation have been reported. Intracranial 
calcification develops in 20% to 48% of patients with 
TBM, usually becoming detectable 2 to 3 years after 
the onset of the disease.29 
Conclusion 
Spectrum of CNS tuberculosis is quite variable and now 
it become relevant for other parts of the world. The 
variable, natural history and accompanying clinical 
features of TBM hinders the early diagnosis. The World 
Health Organization (WHO) estimates that one third of 
the world’s population is infected with mycobacterium 
tuberculosis, with the highest prevalence of 
tuberculosis in Asia, having TBM as one of the most 
common extra pulmonary tuberculosis. TBM continues 
to exact a devastating fall in developed and developing 
countries despite the availability of effective 
chemotherapy. One of the main reason for this failure is 
patients being diagnosed late, when they already have 
many complications of TBM or different types of CNS 
tuberculosis. The increasing problem of drug resistance 
has added a new challenge. The early recognition and 
timely treatment of the disease is critical if the 
considerable mortality and morbidity associated with 
the condition is to be prevented.
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